RGNX
REGENXBIO Inc.Company Information
- Company Name
- REGENXBIO Inc.
- CIK
- CIK0001590877
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- RGNX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- RGNX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-27
- Last sale
- 2026-07-02
- Shares purchased (TTM)
- 53,407
- Shares sold (TTM)
- 95,488
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 42,302,337
- Shares outstanding
- 52,820,000
- Ownership
- 80.09%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -14.36%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 36 | 15 | 34 | 59 | 80 | 130 | 58 | 57 | 58 | 113 | 35 | 53 | ||||||
| Marketable Securities Current | 69 | 135 | 196 | 215 | 244 | 138 | 177 | 199 | 233 | 226 | 241 | 249 | ||||||
| Accounts Receivable Net Current | 107 | 10 | 26 | 25 | 20 | 18 | 20 | 24 | 23 | 16 | 25 | 28 | ||||||
| Prepaid Expense Current | 12 | 12 | 12 | 13 | 11 | 11 | 9 | 11 | 10 | 14 | 15 | 13 | ||||||
| Restricted Cash Current | 0 | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Other Assets Current | 12 | 14 | 13 | 19 | 19 | 16 | 14 | 23 | 23 | 27 | 20 | 23 | ||||||
| Assets Current | 236 | 187 | 281 | 332 | 374 | 313 | 278 | 313 | 347 | 395 | 335 | 366 | ||||||
| Marketable Securities Noncurrent | - | - | 11 | 28 | 40 | 5 | 10 | 23 | 37 | 42 | 39 | 63 | ||||||
| Accounts Receivable Net Noncurrent | 0 | 0 | 2 | 3 | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 98 | 102 | 105 | 108 | 111 | 114 | 118 | 121 | 124 | 128 | 132 | 136 | ||||||
| Operating Lease Right Of Use Asset | 44 | 46 | 47 | 49 | 50 | 52 | 54 | 55 | 56 | 58 | 60 | 62 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 6 | 6 | 5 | 4 | 2 | 3 | 4 | 4 | 3 | 4 | 5 | 5 | ||||||
| Assets | 387 | 342 | 453 | 525 | 581 | 491 | 466 | 519 | 569 | 629 | 574 | 634 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 16 | 21 | 21 | 22 | 22 | 19 | 23 | 20 | 16 | 31 | 23 | 22 | ||||||
| Contract With Customer Liability Current | 10 | 6 | 10 | 13 | 14 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 7 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | ||||||
| Liabilities Current | 83 | 71 | 118 | 125 | 120 | 107 | 103 | 103 | 98 | 110 | 130 | 127 | ||||||
| Contract With Customer Liability Noncurrent | 15 | 23 | 19 | 21 | 24 | 26 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 62 | 63 | 65 | 67 | 70 | 72 | 74 | 76 | 78 | 80 | 82 | 84 | ||||||
| Other Liabilities Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 4 | 3 | 6 | 6 | ||||||
| Liabilities | 315 | 321 | 350 | 364 | 367 | 217 | 206 | 218 | 221 | 239 | 262 | 271 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,266 | 1,238 | 1,229 | 1,221 | 1,211 | 1,201 | 1,193 | 1,183 | 1,172 | 1,162 | 1,021 | 1,013 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -3 | -4 | -7 | ||||||
| Retained Earnings Accumulated Deficit | -1,193 | -1,216 | -1,126 | -1,059 | -997 | -926 | -932 | -881 | -821 | -768 | -705 | -642 | ||||||
| Stockholders Equity | 72 | 21 | 103 | 161 | 214 | 274 | 260 | 301 | 348 | 391 | 312 | 363 | ||||||
| Liabilities And Stockholders Equity | 387 | 342 | 453 | 525 | 581 | 491 | 466 | 519 | 569 | 629 | 574 | 634 | ||||||
| Allowance For Doubtful Accounts Receivable Current | - | - | - | - | - | - | - | - | - | - | 5 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 54 | 52 | 51 | 51 | 50 | 50 | 50 | 50 | 49 | 49 | 44 | 44 | ||||||
| Shares Outstanding | 54 | 52 | 51 | 51 | 50 | 50 | 50 | 50 | 49 | 49 | 44 | 44 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialREGENXBIO Inc. (RGNX) — SEC Financial Statements & Analysis
REGENXBIO Inc. (RGNX) is a biological products, (no diagnostic substances) company. REGENXBIO Inc. trades on Nasdaq as: RGNX. REGENXBIO Inc. (RGNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, REGENXBIO Inc. carries a market cap of $632.78M, a P/E ratio of -3.22x, a P/B ratio of 8.82x, a P/S ratio of 3.63x, an enterprise value of $596.30M, and an EV/EBITDA multiple of -4.01x. On profitability, it posts a gross margin of 59.72%, an operating margin of -94.08%, a net margin of -112.58%, a Return on Equity (ROE) of -137.63%, a Return on Assets (ROA) of -40.60%, and a Return on Invested Capital (ROIC) of -186.53%. Per share, it reports EPS of $-3.72, diluted EPS of $-3.71, free cash flow per share of $-4.73, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 12.00% year-over-year, net income growth of 11.88% year-over-year, and EPS growth of 9.05% year-over-year. On the balance sheet, it maintains a current ratio of 2.86x, a quick ratio of 2.71x, working capital of $153.54M, a debt-to-equity ratio of 4.39x, a debt ratio of 0.81, an interest coverage ratio of -3.91x, free cash flow of $-249.67M (TTM), and net debt of $-36.49M. Figures sourced from SEC EDGAR.
- Market Cap
- $632.78M
- P/E TTM
- -3.22x
- EPS TTM
- $-3.72
- P/B TTM
- 8.82x
- ROE TTM
- -137.63%
- ROA TTM
- -40.60%
- Debt To Equity
- 4.39x
- Free Cash Flow TTM
- $-249.67M
- Net Revenue TTM Growth 1Y
- 12.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is REGENXBIO Inc. in?
REGENXBIO Inc. (RGNX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does RGNX trade on?
REGENXBIO Inc. (RGNX) trades on the Nasdaq.
When was REGENXBIO Inc. (RGNX)'s most recent SEC filing?
REGENXBIO Inc. (RGNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is RGNX's market cap?
REGENXBIO Inc. (RGNX) has a market capitalization of $632.78M as of 2026-06-30.
What is RGNX's EPS (earnings per share)?
REGENXBIO Inc. (RGNX)'s trailing twelve month EPS is $-3.72 as of 2026-06-30.
What is RGNX's ROE (return on equity)?
REGENXBIO Inc. (RGNX)'s trailing twelve month Return on Equity (ROE) is -137.63% as of 2026-06-30.
What is RGNX's ROA (return on assets)?
REGENXBIO Inc. (RGNX)'s trailing twelve month Return on Assets (ROA) is -40.60% as of 2026-06-30.
What is RGNX's ROIC (return on invested capital)?
REGENXBIO Inc. (RGNX)'s trailing twelve month Return on Invested Capital (ROIC) is -186.53% as of 2026-06-30.
What is RGNX's EV/EBITDA?
REGENXBIO Inc. (RGNX)'s trailing twelve month EV/EBITDA is -4.01x as of 2026-06-30.